ARIAD Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals

ARIA 23.99

0.0%

Feb 17 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: James Thompson who wrote (1030)	2/17/2000 6:36:00 PM
From: scott_jiminez	Read Replies (1) of 4474

No problem. Seems like Ariad has been digesting some gains recently. Still appears to be significant potential remaining here given the strength of the platform. With IMNR's Factor XIII news today (I admit to bogarting this info/idea from Aurileano on the Ariad Yahoo thread), it would appear hemophilia could very well be another tailor-made condition for RAPID. A perfect scenario for both low-level chronic release and high-level inducible release...all in one gene therapy based vector. Seems like the potential applications of ARGENT/RAPID are only limited by one's imagination.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next